Brief: ANI Pharmaceuticals Q2 Adjusted EPS USD 1.02 Vs. IBES Estimate USD 0.95
06/08/2024 11:50
Aug 06 (Reuters) - ANI Pharmaceuticals Q2 revenue USD 138.04 million vs. IBES estimate USD 129.1 million. * Q2 operating expenses USD 132.9 million * outlook FY adjusted EPS USD 4.38-4.82 * outlook FY adjusted EBITDA USD 140-150 million
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary